Novel Topical Drug Delivery Systems in Ophthalmic Applications

Rajput, Abhishek; Sharma, Prince; Sharma, Rakesh Kumar; Thakur, Shubham

doi:10.5772/intechopen.108915

Cited by 3 publications

(1 citation statement)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…В последнее время активно ведется исследование применения полоксамеров в системах контролируемой доставки офтальмологических лекарственных препаратов [8]. В технологии глазных лекарственных пленок (ГЛП) полоксамеры, в частности Kol-liphor® P 188, могут использоваться в качестве опционального вспомогательного компонента, повышающего адгезию пленки к эпителию слизистой оболочки конъюктивы и способствующего увеличению проникновения через нее активных веществ [9]. Данные свойства обуславливаются способностью полоксамера образовывать мицеллы с мукопротеидами слезной пленки глазного яблока, что обеспечивает повышение биодоступности лекарственного препарата и пролонгирование его эффекта [6].…”

Section: фармацевтическая технология Pharmaceutical Technologyunclassified

Development of Ocular Inserts Based on Import Substituted Poloxamer Emuxol 268

Bakhrushina,

Turaeva,

Zhalyalova

et al. 2024

Razrabotka i registraciâ lekarstvennyh sredstv

View full text Add to dashboard Cite

Introduction. Emuxol-268 (JSC "NIOPIK", Russia) is a block copolymer produced in Russia with similar in physicochemical and biological properties to poloxamer Kolliphor® P 188 (Pluronic F68) manufactured by BASF, USA. However, a comparison of the properties of natural polymers to assess the prospects of their dosage forms has not been carried out before.Aim. The aim of the study was to demonstrate the interchangeability of auxiliary components using the example of the development of an ophthalmic drug insert by comparing the results of testing the dosage form in terms of such quality parameters as elasticity, thickness, mucoadhesion, pH, biodegradation time and irritation test (hen’s egg-chorioallantoic membrane test, HET-CAM test).Materials and methods. Poloxamers Emuxol 268 (JSC "NIOPIK", Russia) and Kolliphor® P 188 (BASF, Germany), hydroxyethyl cellulose (Natrosol™ 250 HHX, Ashland Global Holdings Inc., USA), and glycerol (LLC "Tulskaya Pharmfabrika", Russia) were used in the experiment. Elasticity, thickness, mucoadhesion, pH, biodegradation time, HET-CAM test were used as screening methods to identify the benefits of the composition.Results and discussion. Experiment results proved that the use of a domestic analogue makes it possible to create an ocular insert with improved quality parameters. The difference in the elasticity index of the inserts differs by 1.3 times, mucoadhesion – 1.7 times, biodegradation time – 2.5 times. In this connection, it can be assumed that an insert based on a domestic polymer contributes to an increase in the time of contact with the eye surface, thereby providing a prolonged effect of the drug and improving its bioavailability. The results obtained may be due to the difference in the average molecular weight of the hydrophobic polyoxypropylene part, which is 2600 Da for Emuxol 268 and 1800 Da for Kolliphor 188. The HET-CAM method showed the same results of the two compositions, both compositions do not have an irritating effect.Conclusion. Summing up, the only analogue of Kolliphor® P 188 available on the Russian pharmaceutical market – Emuxol-268 of JSC NIOPIK is a promising substance for replacement in the development of ophthalmic dosage forms. Despite the differences in physicochemical properties of the domestic block copolymer in comparison with the replaced poloxamer 188, its introduction into placebo inserts gave improved results in terms of quality indicators, which was revealed during a biopharmaceutical analysis.

show abstract

Section: фармацевтическая технология Pharmaceutical Technologyunclassified

Development of Ocular Inserts Based on Import Substituted Poloxamer Emuxol 268

Bakhrushina,

Turaeva,

Zhalyalova

et al. 2024

Razrabotka i registraciâ lekarstvennyh sredstv

View full text Add to dashboard Cite

show abstract

Engineering a novel water-in-oil biocompatible microemulsion system for the ocular delivery of dexamethasone sodium phosphate in the treatment of acute uveitis

Abd-elaty,

Ishak,

Osman

et al. 2024

International Journal of Pharmaceutics

View full text Add to dashboard Cite

A Ride on The Current State of Silver Nanoparticles in Health: What is The Next Stop?

Gil-Korilis,

Ergui-Arbizu

2024

Bioactivities

View full text Add to dashboard Cite

Silver nanoparticles (AgNPs) are known for their broad scientific and technological applications, among which those related to their bioactivity stand out the most. Its antimicrobial, antioxidant, anti-inflammatory, anti-obesity, antifouling, and biosorption properties have been widely studied and analyzed. Furthermore, numerous strategies are being investigated to overcome the main limitation of AgNPs, their cytotoxicity, such as the development of green chemistry synthesis methods using plant extracts or the use of support materials for controlled release of nanoparticles. However, the methodologies currently used in this line of research limit these nanomaterials from eventually being used in the clinic. It is necessary to implement animal models and interdisciplinary collaboration with biomedical research groups to develop therapies based on AgNPs that may be able to have an impact on the health of patients.

show abstract

Novel Topical Drug Delivery Systems in Ophthalmic Applications

Cited by 3 publications

References 64 publications

Development of Ocular Inserts Based on Import Substituted Poloxamer Emuxol 268

Development of Ocular Inserts Based on Import Substituted Poloxamer Emuxol 268

Engineering a novel water-in-oil biocompatible microemulsion system for the ocular delivery of dexamethasone sodium phosphate in the treatment of acute uveitis

A Ride on The Current State of Silver Nanoparticles in Health: What is The Next Stop?

Contact Info

Product

Resources

About